Effects of Red Blood Cell Transfusion Practices on Clinical Outcomes in Extremely Low Gestational Age Infants
Overview
This study investigates the impact of red blood cell transfusion practices on clinical outcomes in extremely low gestational age neonates (ELGANs). It finds that increased transfusions are linked to higher risks of bronchopulmonary dysplasia (BPD) and lower survival rates without severe complications, while a restrictive transfusion strategy is recommended for safer outcomes.
Background
Anemia of prematurity is prevalent in neonatal intensive care units, necessitating red blood cell transfusions. However, transfusions can lead to adverse outcomes, particularly in extremely low gestational age neonates. Understanding the optimal transfusion strategies is crucial for improving clinical outcomes in this vulnerable population.
Data Highlights
Outcome
Adjusted Odds Ratio (OR)
95% Confidence Interval (CI)
p-value
Bronchopulmonary Dysplasia (BPD)
1.88
1.48–2.40
<0.001
Survival without Severe Complications
0.75
0.63–0.91
0.003
Severe Brain Injury
0.62
0.46–0.84
0.002
Mortality
0.66
0.53–0.83
<0.001
Key Findings
63.5% of ELGANs received at least one transfusion, with a median of 2 transfusions per infant.
An increased number of transfusions is an independent risk factor for bronchopulmonary dysplasia (BPD).
Higher transfusion numbers are associated with lower survival rates without severe complications.
Restrictive transfusion strategies resulted in fewer transfusions without increasing adverse outcomes compared to liberal strategies.
No significant association was found between transfusion number and severe retinopathy of prematurity (ROP) or necrotizing enterocolitis (NEC).
Clinical Implications
Clinicians should consider adopting a restrictive transfusion strategy for ELGANs to minimize transfusion exposure while maintaining safety. This approach may help reduce the risk of BPD and improve overall survival without severe complications.
Conclusion
The findings underscore the importance of transfusion practices in managing ELGANs, advocating for a restrictive strategy to enhance clinical outcomes without increasing adverse effects.
